JP7227138B2 - 骨標的抗体 - Google Patents

骨標的抗体 Download PDF

Info

Publication number
JP7227138B2
JP7227138B2 JP2019539277A JP2019539277A JP7227138B2 JP 7227138 B2 JP7227138 B2 JP 7227138B2 JP 2019539277 A JP2019539277 A JP 2019539277A JP 2019539277 A JP2019539277 A JP 2019539277A JP 7227138 B2 JP7227138 B2 JP 7227138B2
Authority
JP
Japan
Prior art keywords
antibody
mab1
seq
antigen
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019539277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505919A5 (enExample
JP2020505919A (ja
Inventor
ファーウェイ・チウ
サングヘー・パーク
ジェームズ・ステファノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2020505919A publication Critical patent/JP2020505919A/ja
Publication of JP2020505919A5 publication Critical patent/JP2020505919A5/ja
Priority to JP2023017271A priority Critical patent/JP7597836B2/ja
Application granted granted Critical
Publication of JP7227138B2 publication Critical patent/JP7227138B2/ja
Priority to JP2024205967A priority patent/JP2025028981A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019539277A 2017-01-20 2018-01-19 骨標的抗体 Active JP7227138B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023017271A JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体
JP2024205967A JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20
US62/448,763 2017-01-20
PCT/US2018/014350 WO2018136698A2 (en) 2017-01-20 2018-01-19 Bone-targeting antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017271A Division JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体

Publications (3)

Publication Number Publication Date
JP2020505919A JP2020505919A (ja) 2020-02-27
JP2020505919A5 JP2020505919A5 (enExample) 2021-02-18
JP7227138B2 true JP7227138B2 (ja) 2023-02-21

Family

ID=61581744

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019539277A Active JP7227138B2 (ja) 2017-01-20 2018-01-19 骨標的抗体
JP2023017271A Active JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体
JP2024205967A Pending JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023017271A Active JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体
JP2024205967A Pending JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Country Status (17)

Country Link
US (3) US10844115B2 (enExample)
EP (1) EP3571226A2 (enExample)
JP (3) JP7227138B2 (enExample)
KR (3) KR102613463B1 (enExample)
CN (2) CN111032690B (enExample)
AR (1) AR110755A1 (enExample)
AU (1) AU2018210270A1 (enExample)
BR (1) BR112019013986A2 (enExample)
CA (1) CA3050884A1 (enExample)
IL (2) IL317592A (enExample)
MX (2) MX2019008549A (enExample)
MY (2) MY207919A (enExample)
SG (1) SG11201906663VA (enExample)
TW (3) TWI788321B (enExample)
UY (1) UY37576A (enExample)
WO (1) WO2018136698A2 (enExample)
ZA (1) ZA201907673B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023058590A (ja) * 2017-01-20 2023-04-25 ジェンザイム・コーポレーション 骨標的抗体

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190216943A1 (en) * 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
CA3120216A1 (en) * 2018-11-19 2020-05-28 Biocartis Nv Enhanced detection of low-copy-number nucleic acids in an integrated workflow
KR20240018471A (ko) 2021-05-07 2024-02-13 베이롤 칼리지 오브 메드신 중등증 내지 중증 불완전 골형성증의 치료
CN117999093A (zh) * 2021-07-20 2024-05-07 威廉马歇莱思大学 用于骨靶向治疗的经改造组合物
US20230144192A1 (en) 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
EP4673179A1 (en) 2023-02-27 2026-01-07 William Marsh Rice University Bone-directed therapeutics for the treatment of cancer
JP7479537B1 (ja) * 2023-03-31 2024-05-08 ナガヨシ製薬株式会社 咳を止め、痰を減らし、免疫力を向上させるイナゴマメ多糖類およびその調製方法と使用
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506028A (ja) 1999-08-02 2003-02-18 エフ． ホフマン−ラ ロシュ アーゲー キメラポリペプチド、その製造方法、およびその使用
JP2008529503A (ja) 2005-02-08 2008-08-07 ジェンザイム・コーポレイション ＴＧＦβに対する抗体
JP2011509084A (ja) 2008-01-03 2011-03-24 ザ スクリプス リサーチ インスティチュート モジュラー認識ドメインを介してターゲティングする抗体
JP2012513377A (ja) 2008-12-22 2012-06-14 ノヴォ・ノルディスク・アー／エス 組織因子経路阻害因子に対する抗体
JP2012524818A (ja) 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
JP2014519524A (ja) 2011-06-13 2014-08-14 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
JP2015502336A (ja) 2011-10-19 2015-01-22 アレクシオン ファーマ ホールディング アルカリホスファターゼ及び／又はナトリウム利尿ペプチドを含む組成物、並びにそれを使用する方法
JP2015519355A (ja) 2012-05-31 2015-07-09 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｔｌｒ３結合剤
JP2016519093A (ja) 2013-03-20 2016-06-30 ジェンザイム・コーポレーション 骨形成不全症の処置方法
WO2018027329A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
KR20050094832A (ko) * 2002-12-31 2005-09-28 알투스 파마슈티컬스 인코포레이티드 단백질 결정과 이온성 중합체를 함유하는 복합체
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CA2632799A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2886607A1 (en) 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EP3119419B1 (en) * 2014-03-17 2019-04-03 Piotr Jachimczak Combination for use in a method of treating cancer
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506028A (ja) 1999-08-02 2003-02-18 エフ． ホフマン−ラ ロシュ アーゲー キメラポリペプチド、その製造方法、およびその使用
JP2008529503A (ja) 2005-02-08 2008-08-07 ジェンザイム・コーポレイション ＴＧＦβに対する抗体
JP2011509084A (ja) 2008-01-03 2011-03-24 ザ スクリプス リサーチ インスティチュート モジュラー認識ドメインを介してターゲティングする抗体
JP2012513377A (ja) 2008-12-22 2012-06-14 ノヴォ・ノルディスク・アー／エス 組織因子経路阻害因子に対する抗体
JP2012524818A (ja) 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
JP2014519524A (ja) 2011-06-13 2014-08-14 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
JP2015502336A (ja) 2011-10-19 2015-01-22 アレクシオン ファーマ ホールディング アルカリホスファターゼ及び／又はナトリウム利尿ペプチドを含む組成物、並びにそれを使用する方法
JP2015519355A (ja) 2012-05-31 2015-07-09 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｔｌｒ３結合剤
JP2016519093A (ja) 2013-03-20 2016-06-30 ジェンザイム・コーポレーション 骨形成不全症の処置方法
WO2018027329A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023058590A (ja) * 2017-01-20 2023-04-25 ジェンザイム・コーポレーション 骨標的抗体
JP7597836B2 (ja) 2017-01-20 2024-12-10 ジェンザイム・コーポレーション 骨標的抗体

Also Published As

Publication number Publication date
MX2022008073A (es) 2022-07-27
US20250074975A1 (en) 2025-03-06
KR102755284B1 (ko) 2025-01-22
KR102613463B1 (ko) 2023-12-15
US12098194B2 (en) 2024-09-24
TWI788321B (zh) 2023-01-01
IL317592A (en) 2025-02-01
IL268114B1 (en) 2025-01-01
MY194819A (en) 2022-12-17
CA3050884A1 (en) 2018-07-26
ZA201907673B (en) 2021-05-26
WO2018136698A2 (en) 2018-07-26
SG11201906663VA (en) 2019-08-27
JP2025028981A (ja) 2025-03-05
IL268114B2 (en) 2025-05-01
EP3571226A2 (en) 2019-11-27
US10844115B2 (en) 2020-11-24
KR20250012197A (ko) 2025-01-23
IL268114A (en) 2019-09-26
RU2019126026A3 (enExample) 2021-11-09
KR20230172039A (ko) 2023-12-21
TW201839013A (zh) 2018-11-01
UY37576A (es) 2018-10-31
US20180208650A1 (en) 2018-07-26
WO2018136698A3 (en) 2018-08-30
JP7597836B2 (ja) 2024-12-10
CN111032690A (zh) 2020-04-17
JP2020505919A (ja) 2020-02-27
AR110755A1 (es) 2019-05-02
MX2019008549A (es) 2019-09-11
TWI832600B (zh) 2024-02-11
AU2018210270A1 (en) 2019-09-05
TW202421659A (zh) 2024-06-01
KR20190105236A (ko) 2019-09-16
RU2019126026A (ru) 2021-02-20
TW202330597A (zh) 2023-08-01
CN111032690B (zh) 2024-03-26
JP2023058590A (ja) 2023-04-25
CN118121696A (zh) 2024-06-04
MY207919A (en) 2025-03-27
BR112019013986A2 (pt) 2020-03-03
US20210163584A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
JP7597836B2 (ja) 骨標的抗体
ES3009519T3 (en) Il-15 and il-15ralpha sushi domain based conjugates
JP7279054B2 (ja) Ｅｄｂ標的化ｉｌ－１２組成物
TW202100557A (zh) 雙互補位ＦＲ-α抗體及免疫結合物
US11623963B2 (en) Cysteine engineered antigen-binding molecules
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
CN110234355A (zh) 单体人IgG1 Fc和双特异性抗体
CN109496149B (zh) 抗体及其药物缀合物的制剂
KR20140120942A (ko) 아밀로이드-베타 펩타이드 항체 제형
JP7458567B2 (ja) Ｃ－ｍｅｔ結合剤
JP2020532523A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
JP2020532543A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
CN120530135A (zh) 抗b7h3抗体和使用方法
JP2025527160A (ja) 多重特異性抗体およびその使用
RU2801206C2 (ru) Антитела, нацеливающиеся на костную ткань
TW202539735A (zh) 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物
TW202325737A (zh) 抗her2的免疫毒素分子及其製備方法與應用
CN121873202A (zh) Il-2突变体、pd1抗体×il-2突变体融合蛋白及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230209

R150 Certificate of patent or registration of utility model

Ref document number: 7227138

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250